MAJIC-PV
MAJIC-PV, a UK academic trial, found that ruxolitinib gave more complete responses than best available therapy and, for the first time, that a complete response went with fewer clots and progressions.
Overview
MAJIC-PV randomised 180 patients with PV resistant to or intolerant of hydroxyurea to ruxolitinib or best available therapy. Complete response within a year, the primary endpoint, was reached by 43 percent on ruxolitinib versus 26 percent on best available therapy; complete responders had better event-free survival (thrombosis, haemorrhage, transformation or death), and the JAK2 V617F allele burden fell more on ruxolitinib (Harrison and colleagues, Journal of Clinical Oncology 2023). Registered as ISRCTN61925716.
- 43 vs 26 out of 100 had no sign of cancer on scans or tests with Ruxolitinib compared with Best available therapy; 17 more per 100.
- Roughly one extra person helped for every 6 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Hydroxyurea-resistant or intolerant polycythaemia vera: ruxolitinib versus best available therapy. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
180 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Complete response within 1 yearprimary | Ruxolitinib | 93 | 43% | - | - | - |
| Best available therapy | 87 | 26% |
Similar pages
not linked directly; found by shared links- TrialRESPONSE-2
Shares Ruxolitinib, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
- TermAquagenic pruritus
Shares Ruxolitinib, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
- TrialRESPONSE
Shares Ruxolitinib, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
- TrialPROUD-PV and CONTINUATION-PV
Shares Clearing the JAK2 clone in polycythaemia vera: interferon plus mutant-selective inhibitors as a route to treatment-free remission, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
- TermPost-PV myelofibrosis (spent phase)
Shares Ruxolitinib, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
- TermErythrocytosis (primary vs secondary)
Shares Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
- TermJAK2 V617F
Shares Ruxolitinib, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
- TermHaematocrit
Shares Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.